Posters

Comparison of visual quality after bilateral implantation of asymmetric refractive bifocal intraocular lenses (IOLs) and diffractive trifocal IOLs

Poster Details

First Author: H.Qi CHINA

Co Author(s):    Y. Gao   Y. Liu   T. Sun   R. Liu   C. Hu   T. Yang     

Abstract Details

Purpose:

To compare the visual quality after bilateral implantation of asymmetric refractive bifocal intraocular lenses (IOLs) and diffractive trifocal IOLs at three months postoperatively, in order to guide the selection of multifocal IOLs for refractive surgery.

Setting:

Peking University Third Hospital

Methods:

Seventy-four cataract patients who wanted to get bilateral implantation of multifocal IOLs were enrolled. According to one's own desire, patients underwent bilateral AT LISA tri 839MP diffractive trifocal IOL (Carl Zeiss Meditec AG) implantation and bilateral SBL-3 asymmetric refractive bifocal IOL (Lenstec, Inc.) implantation were enrolled into Zeiss group and SBL-3 group respectively. Visual acuity, defocus curve, contrast sensitivity, aberrations, spectacle independence and satisfaction questionnaire, and visual function questionnaire were evaluated at three months postoperatively.

Results:

At three months postoperatively, uncorrected near visual acuities was slightly better in SBL-3 group compared with Zeiss group (P = 0.001). At the defocus for 50cm and 40 cm distance visual acuities were better in SBL-3 group (P = 0.042, P = 0.033). Contrast sensitivity were better in Zeiss group under scotopic condition. The total aberrations, high order aberrations, coma and trefoil aberrations were better in Zeiss group (all P < 0.001). Spectacle independence and questionnaire scores were similar in the two groups (P = 0.640, P = 0.125), but satisfaction was higher in Zeiss group (P = 0.012).

Conclusions:

Patients implanted diffractive trifocal IOLs had better satisfaction than patients implanted asymmetric refractive bifocal IOLs, possibly because these patients had better contrast sensitivity under scotopic condition and better aberrations.

Financial Disclosure:

None